Santen Pharmaceutical Co., Ltd. · TSE:4536
Santen Pharmaceutical — J.P. Morgan Healthcare Conference 2019
27 slides from Santen Pharmaceutical's conference presentation, Jan 7, 2019
Slide 1: Protecting the World’s Vision
Protecting the World’s Vision Shigeo Taniuchi President & COO Santen Pharmaceutical Co., Ltd. J.P. Morgan Healthcare Conference January 7, 2019 Copyright© 2018 Santen Pharmaceutical Co., Ltd. All rights reserved.
Slide 2: Disclosure Notice
Disclosure Notice • Information given in presentation contains certain forward-looking statements concerning forecasts, projections and plans whose realization is subject to risk and uncertainty from a variety of sources. Actual results may differ significantly from forecasts. • Business performance
Slide 3: Santen Overall
Santen Overall - Specialized in ophthalmology since 1890 3
Slide 4: Santen’s Values and Mission Statement
Santen’s Values and Mission Statement 1 Values 1 “Exploring the secrets and mechanisms of nature in order to contribute to people’s health” Santen’s original interpretation of a passage from chapter 22 of Zhongyong (The Doctrine of the Mean) by Confucius. We think carefully about what is essential,
Slide 5: Our Contributions to Better Serve Patients in Ophthalmology
Our Contributions to Better Serve Patients in Ophthalmology 2002 2012 2014 2015 2016 2018 PreserFlo1 microshunt Dimple Bottle® Acquisition of Glaucoma products from MSD DE-117 Omidenepag isopropyl Eylea: Co-promoted product of Bayer Yakuhin, Ltd. (MAH) 1PreserFlo is the new name of the pipeline proj
Slide 6: Continuous Growth and Expansion Globally While Contributing to Ophthalmology
Continuous Growth and Expansion Globally While Contributing to Ophthalmology Revenue exceeded Achieved 30% 200 billion yen overseas revenue in FY2017 composition Increased sales regions / countries: Enhanced and advanced pipeline approx. 50→64 FY2013 FY2017 Copyright© 2019 Santen Pharmaceutical Co.,
Slide 7: Santen’s Strength: Ophthalmology
Santen’s Strength OPHTHALMOLOGY Strong and Broad Commitment From front to back of the eye From standard to innovative From compounds to products Capabilities of All kinds of All kinds of Industrialization Disease areas Treatment options Commercialization Globalization Answering the needs in Pr
Slide 8: Answering the Needs in Each Region
Answering the Needs in Each Region EMEA Asia Japan Needs Needs Needs Preservative free products Respond to diverse Latest treatment and environments across countries scientific information for best outcomes Answer Answer Answer Providing products Geographic expansion and Strong and effec
Slide 9: Broad Product Lineup Covering All Disease Areas
Broad Product Lineup Covering All Disease Areas FY2017 Glaucoma Retina Dryeye Allergy Others 28% 28.3% 25% 25.1% 19% 18.9% 9% 9.2% 8.7% 18% 9.8% Glaucoma Retina Dry Eye Allergy Others Cosopt Eylea Diquas Alesion Cravit Kary Uni Oftan Tapros Hyalein Flumetholon Catachrom Trusopt Ikervis Tapcom Cation
Slide 10: Product Development to Satisfy Wide Ranging Needs
Product Development to Satisfy Wide Ranging Needs Improving Treatments Unmet Reducing Patient Burden Medical Needs Santen’s Product Development Santen’s Industry Internal Partner Expertise Open Research Innovation Retinal and Kerato- Institute Refractive Glaucoma Uveal conjunctival disorders disorde
Slide 11: Efficient Product Development
Efficient Product Development Expanding Partnerships globally Chongqing Kerui Pharmaceutical (Group) Co., Ltd. Copyright© 2019 Santen Pharmaceutical Co., Ltd. All rights reserved. 11
Slide 12: Capturing Growth Opportunities
Capturing Growth Opportunities 12
Slide 13: Ophthalmic Industry: Needs and Direction
Ophthalmic Industry: Needs and Direction 81% >50 years old 36 217 Santen growth million million 1/30 of world population 84% Chronic disease opportunities Educational Employment Preventable by 81% opportunity opportunity early detection and treatment Cogan Collection, NEI/NIH Cogan Collection, NEI/N
Slide 14: Key Focus Asia Region
Key Focus 1 Asia Region FY2015 FY2020 FY2030 FY2015 to FY2030 Total Population 3.8 bil 4.0 bil 4.2 bil 1.1x Over 40 Population 1.4 bil 1.5 bil 1.8 bil 1.3x Market Scale* 1.7 bil 2.5~3.0 5.0~6.0 Over 3.0x (USD) bil bil *Asia 18 countries/areas (excluding Japan) *Asia Market Scale : Based on IQVIA MID
Slide 15: Asia Business Strategy
Asia Business Strategy: By Leveraging Santen’s Unique Strength Accelerating growth in Asia supported by experience and knowledge gained in Japan, Europe and US Europe Japan / US Asia Global Influencer Business model supports high -Collaborate with academia and KOLs market share, know-how -Regula
Slide 16: Santen’s Business Expansion in Asia
Santen’s Business Expansion in Asia FY2013 FY2017 FY2020 Direct Sales 3 9 9 Countries/ areas Sales Territories Coverage 10 (countries/ Areas) 14 17 258 475 660 persons Sales Forces (persons) Copyright© 2019 Santen Pharmaceutical Co., Ltd. All rights reserved. 16
Slide 17: Key Focus Glaucoma
Key Focus 2 Glaucoma Global Glaucoma U.S. Demand for Minimally-Invasive Patient Population Glaucoma Surgery (MIGS) Number of Patients, Number of Patients millions 91 80 70 31 27 CAGR 2025 Other 21 +20% 400,000 China glaucoma 36% Primary 60 53 open-angle 49 2015 glaucoma 70,000 2013 2015 2020 Sources
Slide 18: Santen’s Glaucoma Portfolio
Santen’s Glaucoma Portfolio -Positioning to Address All Stages of Glaucoma Mild Moderate Severe Drug Therapies Filtering Surgery treatment Current Trabeculectomy flow 3 Drugs Mono-therapy 2 Drugs or more Tube Shunt Laser Mono Therapies Santen’s future treatment Tapros Timoptol Detantol Trusopt Rescu
Slide 19: Santen’s Latest Work in the Glaucoma Treatment Area
Santen’s Latest Work in the Glaucoma Treatment Area Developing Pipeline with New Value DE-117: First-in-class IOP management DE-128: New implant surgery for POAG Japan: Launched as EYBELIS; Asia: conducting P3; US: Conducting P3 US: conducting P2/3; EU: Soft Launch POAG: primary open angle glaucoma
Slide 20: Santen’s Sustainable Growth into the Future
Santen’s Sustainable Growth into the Future - To become a “Specialized pharmaceutical Company with a Global Presence” 20
Slide 21: Vision 2020: Long-Term Vision Based on Santen’s Values
Vision 2020: Long-Term Vision Based on Santen’s Values 2013 2017 2020 Specialized Pharmaceutical Company with a Global Presence Maximize new global product value グローバル製 品価値最 大化 Build and reinforce overseas businesses Strengthen Japan business framework and competitiveness Copyright© 2019 Santen Phar
Slide 22: Steady Earnings Growth with Ophthalmology Specialization
Steady Earnings Growth with Ophthalmology Specialization Consolidated Results +10% 237 CAGR:% Sales Core OP (JPY billions) 146 +10% 48 30 FY2013 FY2018 Forecast MTP2014-2017 MTP2020 Copyright© 2019 Santen Pharmaceutical Co., Ltd. All rights reserved. 22
Slide 23: Steady Earnings Growth with Ophthalmology Specialization
Steady Earnings Growth with Ophthalmology Specialization Continuous growth in Japan Strong Growth in Asia Rapid growth in EMEA CAGR:% (JPY billions) CAGR:% (JPY billions) CAGR:% (JPY billions) Sales Sales Sales Core OP 8% Core OP Core OP 161 39 36 27% 25% 111 8% +121% 9 +54% 72 11 10 49 12 1 FY2013
Slide 24: Start North America Business with Differentiated Products
Start North America Business with Differentiated Products Differentiated Pipeline/ Products: DE-128, DE-109, DE-117, DE-076C Tailored Strategy to each Pipeline / Product North America +10.2% USD billions, Santen estimates 17.2 > 50% 13.8 8.7 U.S. market trend of the world market #1 growing innov
Slide 25: Pipeline Launch Targets
Pipeline Launch Targets As of January 7, 2019 FY2018 FY2019 FY2020~ DE-117 Japan DE-117 Asia / US Glaucoma DE-126 Japan / US DE-128 US / Europe DE-109 US Retina DE-122 US DE-089 China Dry Eye DE-076B Asia DE-114A Japan Allergy DE-076C Europe DE-076C Canada Others DE-127 Asia Copyright© 2019 Santen P
Slide 26: Protecting the World’s Vision
Protecting the World’s Vision Continuous Journey to Maximize the Joy of Vision All Over the World Always Pursuing Further Contribution to Ophthalmology as a Unique and Specialized Presence in the Field Copyright© 2019 Santen Pharmaceutical Co., Ltd. All rights reserved. 26
Slide 27: Santen
Santen A Clear Vision For Life™
Santen Pharmaceutical — J.P. Morgan Healthcare Conference 2019 on 6ix